Benefits
Vision was measured only in a rare inherited eye disease
The one randomized placebo-controlled trial, RHODOS, gave 900 mg/day or placebo to 85 people with Leber's hereditary optic neuropathy for 24 weeks. It missed its primary endpoint, best recovery of visual acuity. A post hoc interaction analysis found the secondary endpoints differed from placebo only in patients whose two eyes had discordant visual acuity at baseline. European regulators gave the first application a negative opinion and the company withdrew it in March 2013; a later application was authorised in 2015 under exceptional circumstances. FDA has not approved it and asked for more data in 2026. Nothing here was measured in ordinary eyesight.
Mitochondrial bioenergetics support
Idebenone carries the quinone head of CoQ10 on a shorter side chain, which makes it more water-soluble. In the laboratory it accepts electrons by way of the enzyme NQO1 and passes them to Complex III. That chemistry is why it was tested in diseases involving Complex I. It has not been shown to change energy, fatigue or any other outcome in people who do not have such a disease.
The trials in an inherited nerve disease failed
Two phase 3 trials in Friedreich's ataxia missed their primary endpoints: IONIA in 70 children and adolescents, and MICONOS in 232 mostly adult patients, which reported failure in 2010. European regulators issued a negative opinion on the marketing application in July 2008 and confirmed the refusal on re-examination in November 2008. Canada had granted a conditional approval in July 2008, and after the trial results the manufacturer agreed with Health Canada to withdraw the product, ending sales on 30 April 2013. It is approved for this disease nowhere.
Skin creams are a different route and say nothing about capsules
Idebenone is used at 0.5 to 1 percent in cosmetic face serums, and the small studies behind that use applied it to the skin. Its ranking above vitamin C, vitamin E and CoQ10 comes from test-tube antioxidant assays such as ORAC, not from people. Putting a compound on the face and swallowing it are different routes, and the skin results do not transfer to an oral capsule.
Mechanism of action
Bypass of Complex I dysfunction in mitochondrial respiratory chain
Idebenone's reduced form transfers electrons from cytoplasmic NAD(P)H, by way of the enzyme NQO1, into Complex III, bypassing Complex I. That was the rationale for testing it in Leber's hereditary optic neuropathy, where mitochondrial DNA mutations disable Complex I. It is a rationale for running a trial, not a demonstrated effect in people whose mitochondria work normally.
Antioxidant activity (lipid peroxidation prevention)
Both the reduced and oxidised forms scavenge reactive oxygen species in lipid environments. In cell-free and cell-culture systems idebenone limits membrane lipid peroxidation, regenerates vitamin E in the same way ubiquinol does, and outscores CoQ10 on antioxidant assays. These are laboratory measurements. No trial has measured an antioxidant marker in people taking idebenone by mouth.
ATP production support in mitochondrial dysfunction
Stimulates mitochondrial electron transport flux when Complex I is impaired, supplementing cellular ATP levels. Most relevant in tissues with high energy demand (retinal ganglion cells in LHON, cardiomyocytes in FRDA cardiomyopathy, neurons in mitochondrial encephalopathies). Effect size depends on the degree of Complex I impairment, and it is minimal in healthy mitochondria.
NQO1 substrate (cytoplasmic redox)
Unlike CoQ10, idebenone is an efficient substrate for NQO1 (NAD(P)H:quinone oxidoreductase 1), allowing reduction in cytoplasm. This produces a 'cytoplasmic-mitochondrial shuttle' for electrons that's specific to idebenone. NQO1 activity varies between people. In cultured cells and in isolated mouse retina, cells low in NQO1 not only failed to activate idebenone but lost viability when exposed to it, with reactive oxygen production and falling ATP, which points to a narrow window rather than a simple lack of response.
Clinical trials
Phase III randomized, double-blind, placebo-controlled trial (Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, Kernt M, Petraki D, Rummey C, Leinonen M, Metz G, Griffiths PG, Meier T, Chinnery PF 2011, Brain 134(Pt 9):2677-2686, doi:10.1093/brain/awr170). NCT00747487.
85 LHON patients ≥14 years with one of the three primary mtDNA mutations (m.11778G>A, m.3460G>A, m.14484T>C) and first vision loss within 5 years. Randomized 2:1 to idebenone 900 mg/day vs placebo for 24 weeks.
The primary endpoint, best recovery of visual acuity, did not reach statistical significance in the intention-to-treat population. A post hoc interaction analysis showed a different response in patients whose two eyes had discordant visual acuity at baseline, and in that group the secondary endpoints differed significantly from placebo. The subgroup was defined by baseline acuity, not by mutation. Idebenone was safe and well tolerated over the 24 weeks.
Phase 3 double-blind, randomized, placebo-controlled trial (Lynch DR, Perlman SL, Meier T 2010, Arch Neurol 67(8):941-947, doi:10.1001/archneurol.2010.168). NCT00537680. Conducted with Santhera Pharmaceuticals, which developed the drug.
70 ambulatory patients aged 8 to 18 with Friedreich's ataxia and a baseline ICARS score of 10 to 54. Randomized to placebo (n=24), to 450 or 900 mg/day by body weight (n=22), or to 1,350 or 2,250 mg/day by body weight (n=24), for 24 weeks.
The primary endpoint was missed. Mean ICARS score improved by 2.5 points on idebenone and by 1.3 points on placebo, and FARS improved by 1.6 points on idebenone while declining by 0.6 points on placebo. Neither difference was statistically significant. The authors concluded that idebenone did not significantly alter neurological function over the 6 months. A separate 12-month open-label extension had no placebo group and cannot show efficacy.
Multicentre double-blind placebo-controlled trial, 'Idebenone in senile dementia of Alzheimer type: a multicentre study' (Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denaro M, Marigliano V, Tammaro AE, Fioravanti M 1992, Arch Gerontol Geriatr 15(3):249-260).
102 elderly patients with mild or moderate Alzheimer's-type dementia, randomized to idebenone 45 mg twice daily (90 mg/day) or placebo for 4 months.
This 1992 trial reported significant improvement in memory, attention and behaviour on 90 mg/day. It was not confirmed. A 1-year trial in 536 patients using 360, 720 or 1,080 mg/day found no significant difference from placebo on either primary outcome in its prespecified four-group design, and none on any secondary outcome, and concluded that idebenone failed to slow cognitive decline. The dementia indication was abandoned.